Mylan has reported that its subsidiary, Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Levetiracetam tablets, 1000mg. Levetiracetam tablets
GlaxoSmithKline (GSK) has reported Phase III study results which showed that women with an aggressive form of breast cancer experienced a median survival of 14 months, when treated
Neoprobe’ researchers, who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek, have presented data from their clinical experience at the International San
Pyng Medical (Pyng) has received CE Mark for Cric Cricothyroidotomy Kit to sell into the European market. The Cric provides a one-handed Cricothyroidotomy solution including illumination and built
AbSorber has received patent protection for its transplantation cross match-test XM-One in the European countries. Reportedly, the patent was previously approved in New Zealand which was the first
AgraQuest and Bayer CropScience have entered into a supply agreement. As per the terms of the agreement, AgraQuest will produce and package products for the new Natria product
Cytokinetics has agreed with GlaxoSmithKline (GSK) to terminate their collaboration and license agreement, effective February 28, 2010. As a result, all rights for GSK-923295, an inhibitor of centromere-associated
Dishman Pharmaceuticals and Chemicals has entered into a joint venture with three pharmaceutical companies in Saudi Arabia. The new venture will manufacture active pharmaceutical ingredients (API), reported Business
Critical Outcome Technologies (COTI) has announced positive results from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the
Sanofi-aventis and Alopexx Pharmaceuticals have entered into a collaboration agreement and option for a license on a first-in-class human monoclonal antibody for the prevention and treatment of S
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.